Drug Type Monoclonal antibody |
Synonyms BMS 986226, BMS-986226 |
Target |
Action antagonists |
Mechanism ICOS antagonists(Inducible T-cell costimulator antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 01 Sep 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Canada | 01 Sep 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Spain | 01 Sep 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Switzerland | 01 Sep 2017 |
Phase 1/2 | 80 | (Preliminary - BMS-986226 2 mg) | ssnplkrfvo = mbdbxtkthq zsggawszcl (qejavwlbib, njgldkgzjz - zttmxbzeca) View more | - | 28 Feb 2023 | ||
(Preliminary - BMS-986226 8 mg) | ssnplkrfvo = felznktynm zsggawszcl (qejavwlbib, yrmoppyuqq - hmatphioeq) View more |